Article
On-demand use of a phosphodiesterase type-5 inhibitor did not affect prostatic or urinary outcomes of therapy for BPH, a post hoc analysis of a large randomized trial showed.
FDA reports Urgent Field Safety Notice on mini PCNL sheath
Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults
Investigators identify potential dual targets in prostate cancer
Former MLB player Dave Winfield shares lessons from baseball, philanthropy
FDA greenlights phase 1/2 trial of gene editing therapy for primary hyperoxaluria 1
NCCN reaffirms Prolaris’ prognostic value in prostate cancer